EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Innovative Approaches to NAFLD : Exploring the Role of Nicotinamide in Multicellular Microtissue Models of Liver Fibrosis

Farnaz Sani iD, Shima Parsa, Kimia Falamarzi, Mohammadhossein Khorraminejad-Shirazi, Negar Azarpira, Mahsa Sani iD

Journal of Cellular and Molecular Medicine · 2025

DOI: 10.1111/jcmm.70606 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Farnaz Sani und 5 weiteren Autor:innen. Beteiligte Einrichtung: Shiraz Institute for Stem Cell & Regenerative Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. Hauptthemen laut MEDLINE: Niacinamide, Non-alcoholic Fatty Liver Disease, Liver Cirrhosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Medical Research Development (NIMAD).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In non‐alcoholic fatty liver disease (NAFLD), characterised by progressive liver damage, inflammation, fibrosis and potential cirrhosis, treatment options are limited, with liver transplantation as the only definitive solution. To address this urgent need, in vitro and tissue engineering studies have explored new drugs. This study investigated the anti‐inflammatory and anti‐fibrotic potential of Nicotinamide, utilising promising preliminary data for treating NAFLD. Multicellular liver microtissues comprising LX2 stellate cells, HepG2 hepatocytes and HUVECs were generated to establish a robust preclinical model for fibrosis. Cell viability and histological assessments confirmed successful co‐aggregation within the microtissues. To induce fibrosis, they were treated with a palmitic and oleic acid mixture, followed by exposure to Nicotinamide. Treatment effectiveness was evaluated by analysing inflammatory factors, including transforming growth factor β1 (TGF‐β1), tumour necrosis factor‐alpha (TNF‐α) and interleukin 1 beta and interleukin 6. Extracellular matrix deposition was assessed by measuring collagen type I (COL I) and α‐smooth muscle actin (α‐SMA). Our data suggested that Nicotinamide application led to significant improvements across several measures. Specifically, it effectively reduced inflammatory response by reducing TGF‐β1 levels and decreasing COL I and α‐SMA levels. Furthermore, Nicotinamide was crucial in reducing reactive oxygen species levels, indicating that activation of HSC, inflammatory signals and oxidative stress work together. These in vitro findings suggest Nicotinamide may have therapeutic potential warranting further investigation in advanced preclinical models. Our findings demonstrated significant improvements across various parameters, including reduced expression of pro‐inflammatory cytokines and attenuated oxidative stress, underscoring the therapeutic potential of Nicotinamide in clinical studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NiacinamideNon-alcoholic Fatty Liver DiseaseLiver CirrhosisHumansHep G2 CellsHepatic Stellate CellsHuman Umbilical Vein Endothelial CellsTransforming Growth Factor beta1Models, BiologicalHepatocytesActinsCell SurvivalCollagen Type IInflammation

Stichwörter der Autor:innen

NAFLDNASHTGF‐β1liver fibrosismicrotissuenicotinamide

Substanzen

NiacinamideTransforming Growth Factor beta1ActinsCollagen Type I

Autor:innen und Institutionen

  • Shiraz Institute for Stem Cell & Regenerative Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston Salem, North Carolina, USA.
  • Zoonoses Research Center, Jahrom University of Medical Sciences, Jahrom, Iran.
  • Department of Pathology, School of Medicine, Jahrom University of Medical Sciences, Jahrom, Iran.
  • Department of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.

ORCID-Profile: Farnaz Sani, Mahsa Sani

Förderung

  • National Institute for Medical Research Development (NIMAD)

Zitieren

APA

Sani, F., Parsa, S., Falamarzi, K., Khorraminejad-Shirazi, M., Azarpira, N., & Sani, M. (2025). Innovative Approaches to NAFLD : Exploring the Role of Nicotinamide in Multicellular Microtissue Models of Liver Fibrosis. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70606

Vancouver

Sani F, Parsa S, Falamarzi K, Khorraminejad-Shirazi M, Azarpira N, Sani M. Innovative Approaches to NAFLD : Exploring the Role of Nicotinamide in Multicellular Microtissue Models of Liver Fibrosis. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70606

BibTeX
@article{Sani2025,
  author = {Sani, Farnaz and Parsa, Shima and Falamarzi, Kimia and Khorraminejad-Shirazi, Mohammadhossein and Azarpira, Negar and Sani, Mahsa},
  title = {Innovative Approaches to NAFLD : Exploring the Role of Nicotinamide in Multicellular Microtissue Models of Liver Fibrosis},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2025},
  doi = {10.1111/jcmm.70606}
}
Kostenlos starten →